ImmunityBio filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration on March 9, 2026 to seek approval for ANKTIVA plus BCG in patients with BCG‑unresponsive papillary non‑muscle invasive bladder cancer (NMIBC). The FDA has acknowledged receipt of the filing, and the resubmission follows a series of discussions that began in January 2026 when the agency requested additional data to support the review.
The resubmission incorporates updated efficacy data from the QUILT 3.032 Phase 2/3 trial. In Cohort B, which enrolled high‑grade papillary‑only NMIBC patients, the combination achieved a 12‑month disease‑free survival rate of 58.2% and a 36‑month disease‑specific survival rate of 96.0%. Cystectomy avoidance was 81.8% at 36 months, underscoring the product’s potential to provide durable bladder‑sparing outcomes and a chemotherapy‑free alternative for high‑risk patients.
Papillary disease represents roughly 70 % of the estimated 60,000 U.S. NMIBC cases each year, and the high‑risk NMIBC market is valued at about USD 1.6 billion. Expanding the indication to include papillary‑only disease could therefore unlock a substantial new revenue stream for ImmunityBio, complementing its existing carcinoma‑in‑situ (CIS) indication and broadening the product’s commercial reach.
ANKTIVA competes with other BCG‑unresponsive NMIBC therapies such as Keytruda (pembrolizumab), Adstiladrin (nadofaragene firedenovec), and CG Oncology’s cretostimogene grenadenorepvec. Unlike these agents, ANKTIVA delivers an IL‑15 superagonist that stimulates innate and adaptive immune responses, offering a distinct mechanism that may translate into higher efficacy and lower toxicity.
Financially, ImmunityBio’s Q4 2025 earnings beat expectations, reporting revenue of USD 38.29 million and a net loss of USD 351.4 million for the full year, a 700 % increase in revenue year‑over‑year. The company guided 2026 Q2 and Q3 revenue to USD 51.36 million and USD 60.01 million, respectively, and EPS guidance of –$0.07 for each quarter. The earnings beat was driven by strong demand for ANKTIVA, disciplined cost management, and a favorable product mix that offset broader market headwinds.
Dr. Patrick Soon‑Shiong has highlighted ANKTIVA’s IL‑15 superagonist activity as a key differentiator, emphasizing its potential to provide a chemotherapy‑free, durable bladder‑sparing option for patients with high‑risk NMIBC. The company’s leadership views the sBLA resubmission as a critical step toward expanding the product’s therapeutic footprint.
Analysts have responded to the regulatory milestone by raising price targets for ImmunityBio, reflecting confidence in the company’s growth trajectory and the expanding market opportunity for ANKTIVA.
The sBLA resubmission marks a significant regulatory milestone that could broaden ANKTIVA’s market reach and reinforce ImmunityBio’s position in the high‑risk NMIBC space, potentially driving future revenue growth and strengthening investor confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.